MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...
Genomic assays have become indispensable tools in the management of early-stage invasive breast cancer, helping oncologists ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
While several studies have demonstrated that the Oncotype DX Recurrence Score can help predict locoregional recurrence in patients with hormone receptor-positive breast cancer, it’s less clear whether ...
Gene expression testing, such as Oncotype DX, aids in chemotherapy decisions for hormone receptor-positive breast cancer, though challenges exist for premenopausal patients with scores under 25.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results